Flutamide
-
Subject Areas on Research
- A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.
- Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
- An intergenerational androgenic mechanism of female intrasexual competition in the cooperatively breeding meerkat.
- Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line.
- Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy.
- Androgens and masculinization of genitalia in the spotted hyaena (Crocuta crocuta). 2. Effects of prenatal anti-androgens.
- Beyond aggression: Androgen-receptor blockade modulates social interaction in wild meerkats.
- Biochemical recurrence of prostate cancer.
- Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy.
- Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
- Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
- Effects of neoadjuvant hormonal therapy on prostate biopsy results after (125)I and (103)Pd seed implantation.
- Effects of prenatal treatment with antiandrogens on luteinizing hormone secretion and sex steroid concentrations in adult spotted hyenas, Crocuta crocuta.
- Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.
- Evaluation of chemicals with endocrine modulating activity in a yeast-based steroid hormone receptor gene transcription assay.
- Exposure to naturally circulating androgens during foetal life incurs direct reproductive costs in female spotted hyenas, but is prerequisite for male mating.
- Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer.
- Inhibition of androgen receptor-dependent transcriptional activity by DDT isomers and methoxychlor in HepG2 human hepatoma cells.
- Ligand-specific dynamics of the androgen receptor at its response element in living cells.
- Massive locally extensive prostate cancer.
- Molecular implications of the antiandrogen withdrawal syndrome.
- Neoadjuvant hormone therapy: the Canadian trials.
- Reduction of granulosa cell progesterone secretion in vitro by intraovarian implants of antiandrogen.
- Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.
- The anti-androgen combination, flutamide plus finasteride, paradoxically suppressed LH and androgen concentrations in pregnant spotted hyenas, but not in males.
- Treatment considerations for persons with metastatic prostate cancer: survival versus out-of-pocket costs.
- p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).